可溶性清道夫受体A参与抑制T细胞活化治疗慢性乙型肝炎

StephenW

  Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B


Scavenger receptor A (SRA) is expressed predominantly in phagocytic cells playing an essential role in the host immune defense against invading microorganisms. Our previous study reported the presence of SRA in a soluble form in patients with infection of hepatitis B viruses (HBV).

However, the association of soluble SRA with stages of HBV infection and the immune response induced by HBV is not fully determined.

Methods: In this study, we detected soluble SRA in serum from 29 chronic hepatitis B (CHB) patients, 28 chronic HBVcarriers in the immune tolerant (IT) stage, 33 in the HBeAg-negative inactive carrier (IC) stage, and 22 healthy controls (HCs), respectively. We further analyzed the correlation of detected soluble SRA to inflammation and serum viral load.

In addition, we investigated the regulatory role of soluble SRA in T cell activation, especially in CD8+ T cell response to HBV peptide.

Results: We demonstrated that Median levels of serum soluble SRA in CHB and IT patients were significantly higher than those of IC patients and HCs. Additionally, the concentrations of soluble SRA were negatively correlated with alanine transaminase levels in CHB patients.

We also found that serum concentration of SRA was decreased during telbivudine treatment. Expressed SRA extracellular domain suppressed HBV core peptide-stimulated interferon-γand tumor necrosis factor-αproduction in CD8+ T cells, and it bound to T cells in a higher frequency in CHB patients than in HCs.

Furthermore, we observed that naïve human T cells stimulated by anti-CD3 and CD28 antibodies in the presence of the recombinant SRA protein had reduced activation and proliferation.

Conclusion: In summary, we determined the level of soluble SRA in different stages of CHB patients. SRA might inhibit T cell proliferation and activation as a soluble form.

These results not only revealed a previously unknown feature of soluble SRA in CHB patients but also provided broad understanding of SRA in T cell activation.

Author: Ying ChenZuxiong HuangDi MaLiqian ChenQintao LaiXuan HuangJia ZhouXiaoyong ZhangQiang MaZhengliang ChenDaming Zuo
Credits/Source: BMC Immunology 2015, 16:29

StephenW

可溶性清道夫受体A参与抑制T细胞活化治疗慢性乙型肝炎


清道夫受体A（SRA）主要表达在吞噬细胞发挥在宿主免疫防御至关重要的作用抵御入侵的微生物。我们以前的研究报告的SRA的可溶形式存在于患者的乙型肝炎病毒（HBV）感染。

然而，可溶性SRA与HBV感染和诱导乙型肝炎病毒的免疫反应阶段的关联未完全确定。

方法：在这项研究中，我们发现可溶性SRA血清中29慢性乙型肝炎（CHB）患者，在免疫耐受的慢性28 HBVcarriers（IT）阶段，在HBeAg阴性活性载体（IC）级33，和22例健康对照（碳氢化合物），分别。我们进一步分析的检测可溶性SRA炎症和血清病毒载量的相关性。

此外，我们研究了可溶的SRA的在T细胞活化的调节作用，特别是在CD8 + T细胞应答对HBV肽。

结果：我们表明，血清可溶性SRA的CHB位数水平和IT的患者均高于IC患者和碳氢化合物的显著高。此外，可溶性SRA的浓度呈负慢性乙型肝炎患者谷丙转氨酶水平相关。

我们还发现，SRA的血清浓度在替比夫定治疗减少。表示SRA细胞外结构域抑制HBV核心肽刺激干扰素γand肿瘤坏死因子-I±生产中CD8 + T细胞，并将其结合到T细胞中更高的频率在慢性乙型肝炎患者比碳氢化合物。

此外，我们观察到，通过抗CD3和CD28抗体在重组的SRA蛋白的存在下刺激的天真的人T细胞减少了活化和增殖。

结论：综上所述，我们确定可溶性SRA的慢性乙型肝炎患者的不同阶段的水平。 SRA可能抑制T细胞增殖和活化的可溶形式。

这些结果不仅揭示可溶性SRA的慢性乙肝患者一个先前未知的功能，但也提供了SRA的T细胞活化广泛的理解。

作者：英ChenZuxiong黄帝MaLiqian ChenQintao LaiXuan皇嘉ZhouXiaoyong张强MaZhengliang ChenDaming左
积分/来源：BMC免疫学2015年，16:29